Moreover, a steady decline of DAT was previously reported in asymptomatic LRRK2 G2019S mutation carriers, comparable to the rate in patients converting to PD, which was determined by lower baseline striatal DAT availability [30,31]. This evidence concerns the gene SLC6A3 and Parkinson disease.